Preemptive Therapy of GVHD
Preemptive Therapy of Graft-vs-Host Disease Using Rabbit Antithymocyte Globulin
Sponsor: Alberta Health services
Terminated
The trend was observed toward higher mortality among the patients receiving the intervention Thymoglobulin on day 8 after hematopoietic cell transplantation.
Other terminated trials from Alberta Health services
A PHASE2 clinical study on Graft-vs-host Disease, this trial is terminated or withdrawn. The trial is conducted by Alberta Health services and has accumulated 10 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
-
Nov 2022 — Dec 2023 [monthly]
Unknown Status PHASE2
-
Jan 2021 — Nov 2022 [monthly]
Unknown Status PHASE2
▶ Show 5 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
Status: Suspended → Active Not Recruiting
-
May 2018 — Jun 2018 [monthly]
Suspended PHASE2
-
Aug 2017 — May 2018 [monthly]
Suspended PHASE2
-
Jan 2017 — Aug 2017 [monthly]
Suspended PHASE2
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alberta Health services
- University of Alberta
- University of Calgary
For direct contact, visit the study record on ClinicalTrials.gov .